Ian F. Tannock - Concepedia

Author

Ian F. Tannock

Also Known As

I F Tannock, I TANNOCK, I Tannock, I. F. Tannock, I. TANNOCK, I. Tannock, I.F Tannock, I.F. Tannock, IAN F. TANNOCK, IF Tannock

616

Publications

61.7K

Citations

110

H-Index

263

Concepts

All Affiliations

Princess Margaret Cancer Centre University of Toronto Ontario Institute for Cancer Research University Health Network Johns Hopkins University

About

Ian F. Tannock is an author at Princess Margaret Cancer Centre specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	29	42	3.4K
2	Engineering	3	3	402
3	Education	2	2	133
4	Business	1	1	40
5	Management	1	1	40

Ian F. Tannock

273

Publications

40.7K

Citations

H-Index

Page 1

	Year	Citations
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Ian F. Tannock, Ronald de Wit, William R. Berry, New England Journal of Medicine	2004	5.7K
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Howard I. Scher, Susan Halabi, Ian F. Tannock, Journal of Clinical Oncology	2008	2.2K
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial Camilla Zimmermann, Nadia Swami, Monika K. Krzyzanowska, The Lancet Palliative CareFamily MedicineAdvanced CancerCluster-randomised Controlled TrialEnd-of-life Care	2014	1.7K
Acid pH in tumors and its potential for therapeutic exploitation. Ian F. Tannock, Daniela Rotin PubMed PathologyCell ProliferationCellular PhysiologyTumor BiologyCancer Cell Biology	1989	1.6K
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study Dominik Berthold, Gregory R. Pond, Freidele Soban, Journal of Clinical Oncology	2008	1.1K
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Fadlo R. Khuri, John Nemunaitis, Ian Ganly, Nature Medicine Intratumoral Onyx-015Neck CancerMedicinePathologyHead And Neck Cancer	2000	1.1K
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Patrick J. Loehrer, Lawrence H. Einhorn, Paul Elson, Journal of Clinical Oncology	1992	984
The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour Ian F. Tannock British Journal of Cancer AngiogenesisXenotransplantationMammary GlandCell ProliferationBreast Cancer	1968	765
Delivering affordable cancer care in high-income countries Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, The Lancet Oncology Health PolicyUniversal Health CareHealth InsuranceHealth FinancingPublic Health	2011	701
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, European Urology	2017	636

Page 1